Index

• Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
• Xilio Therapeutics Announces FDA Clearance of Investigational New Drug Application for XTX202 for the Treatment of Solid Tumors
• Funnel, a no-code tool for marketers to organize disparate data sources, raises $66M in ‘pre-IPO’ round
• Cytek® Biosciences Introduces New 25-Color Immunoprofiling Assay
• GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
• Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases
• Atalanta Therapeutics Strengthens Leadership Team with Key Appointments in R&D and Corporate Development
• Affinia Therapeutics Appoints Carole Faig to Board of Directors
• Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate CHS-201 to Reference Product Lucentis® (Ranibizumab) in the Treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Presented at Retina Society Annual Scientific Meeting
• Embark Veterinary Launches First-Ever DNA Test for Purebred Dog Owners
• Firefly Health Launches Health Plan for Employers
• Zenflow Launches Pivotal Clinical Trial of Minimally Invasive Spring® Treatment for Enlarged Prostate Symptoms
• NOCD Expands OCD Awareness Week Programming to Run Throughout October
• Devoted Health Brings Its Next-Generation Medicare Advantage Plan to Illinois
• Solid tumor biotech Xilio Therapeutics files for a $100 million IPO
• Burro raises $10.9M for autonomous produce field transport
• Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
• Behavioral Health Leader Christina Mainelli Joins Quartet Health to Accelerate Strategic Growth
• Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer
• Verve Therapeutics Announces Development of Proprietary GalNAc-LNP Delivery Technology Enabling Efficient In Vivo Liver Delivery of Base Editors
• Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis
• Restaurant-software maker Toast valued at nearly $33 bln as shares surge in debut
• Owkin’s deep learning AI predicts chances of metastatic breast cancer relapse within next 5 years
• Centivo raises $51 million as more employers seek affordable, quality healthcare for their employees
• NOCD Raises $33 Million to Address Global OCD Crisis; Series B Financing to Support People Struggling with OCD, Fuel Growth
• Emvitals Partners with SonderMind to make mental healthcare more accessible
• WellAir announces agreement with Vizient, Inc. to help expand air and surface disinfection technologies to healthcare facilities
• MISMO, Snapdocs Announce Collaboration on New e-Eligibility Service
• Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
• Innovent Releases Interim Analysis Results of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in the Phase 3 ORIENT-16 Study at ESMO Congress 2021
• Indian online pharmacy PharmEasy buys cloud-based hospital supply chain management startup Aknamed
• Acacia Pharma Announces Initiation of Pivotal Study of Byfavo® in Pediatric Procedural Sedation
• Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors
• Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
• Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
• IPO-bound online pharmacy startup PharmEasy makes its third big acquisition this year
• Owkin Enters Into Agreement to Build Innovative Methods With the Potential to Enhance AI-Enabled External Control Arms
• Benchling Expands into Early Development Market to Accelerate Delivery of Breakthrough Products
• Kyruus Broadens its Online Scheduling Platform to Allow Consumers to Self-Book Diagnostic and Preventive Care Appointments
• Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event
• Proximie Selects 8×8 Call and Video Quality Performance Monitoring to Enhance Future of Surgical Healthcare
• Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
• Restaurant-software provider Toast aims for over $16 bln valuation in U.S. IPO
• Dr. Patrice Harris Joins Quartet Health’s Board of Directors
• RareCyte® Secures $24M Financing to Advance the Orion™ Spatial Biology Platform and Expand Global Commercial Channels
• Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS
• Inovia Capital Partner and Former RIM CFO and COO Dennis Kavelman Joins BenchSci Board of Directors
• Flywire Announces Flywire Forward, a Virtual Event Focused on the Future of FinTech
• Proximie Partners with Teladoc Health to Connect Operating Rooms Globally
• Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies
• Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets
• Snapsheet Joins NVIDIA Inception to Accelerate the Development of AI Models that Automate Claims Management Processes for Insurers
• Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group
• SoulBeing Joins Buoy Health’s Marketplace to Offer Alternative Medicine Services to Consumers
• Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation
• Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China
• Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
• Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
• One Medical Completes Acquisition of Iora Health
• Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline
• Benchling Names Salesforce Executive Lindsey Irvine as Chief Marketing Officer
• Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)
• Oviva grabs $80M for app-delivered healthy eating programs
• AppliedVR taps Curebase to run at-home clinical trials testing VR for pain treatment
• Nocion Therapeutics Announces Dosing Underway in Participants with Chronic Cough
• Insilico Medicine taps 4B Technologies’ neurological know-how to build AI-designed ALS drugs
• Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN
• Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors
• NYCM Insurance Launches Snapsheet Payments Software to Enable Digital Payment Options for Claimants and Vendors
• Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
• Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)
• NFlection Therapeutics Announces Orphan Drug Designation of NFX-179 for the Treatment of Cutaneous Neurofibromatosis Type 1
• Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
• Fertility Startup Carrot Raises $75 Million In A Series C Round
• Flywire Survey: Majority of Americans Want Consumer-Friendly Ways to Pay for Healthcare
• Branch Insurance Partners with Snapsheet Claims Platform to Accelerate the Claims Experience
• Xilio Therapeutics Appoints Sara Bonstein to Its Board of Directors
• As US review of Eli Lilly-partnered PD-1 gets underway, Innovent touts another frontline win in China
• Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use
• Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
• Innovusion Raises $66 Million in Series B Plus Financing to Accelerate the Global Adoption of Autonomous Transportation
• Vanessa Ribreau Joins BenchSci as Chief People Officer to Lead Company’s Embrace of the Future of Work
• The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director
• 1upHealth Announces Free Baseline Testing for Health Plans to Determine if their Patient Access FHIR® API is Successfully Connecting as Required by CMS
• Whatfix Closes Nittio Learn Acquisition During Record Quarter in Q2, 2021
• Beam Therapeutics Is Aiming To Start Human Trials For Its Sickle Cell Treatment
• WellAir Appoints Kari Dixon as Chief Financial Officer
• MaxCyte Signs Clinical and Commercial License with Sana Biotechnology
• Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas
• Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors